ORLADEYO收入增长 - 第二季度ORLADEYO净收入同比增长34%至1.083亿美元[7] - 公司将2024年全年ORLADEYO收入指引上调至4.2-4.35亿美元(之前为3.9-4亿美元)[2] - ORLADEYO在欧洲和拉丁美洲获得更多批准和报销授权,现已在20多个国家上市,第二季度海外ORLADEYO收入同比增长51%,占全球ORLADEYO净收入的11%[11] - 2024年第二季度ORLADEYO收入为1.08亿美元，同比增长33.6%[40] - 2024年上半年ORLADEYO收入为1.97亿美元，同比增长31.9%[40] 盈利能力 - 公司在第二季度实现GAAP营业利润880万美元(非GAAP营业利润2190万美元)[24] - 公司有信心在2024年实现全年营业利润(不含非现金股票补偿),并在2025年下半年接近季度性正EPS和正现金流,2026年全年实现盈利和正现金流[34] - 2024年第二季度经营利润为876万美元，而2023年同期为亏损2070万美元[41] - 2024年第二季度每股调整后亏损为0.06美元，2023年同期为0.24美元[47] 费用管控 - 公司预计2024年全年营业费用将保持在3.65-3.75亿美元之间,与2023年持平[32] - 2024年第二季度研发费用为3760万美元，同比减少26.6%[41] - 2024年第二季度销售及管理费用为6120万美元，同比增长20.0%[41] 现金流及财务状况 - 公司不打算动用Pharmakon提供的额外1.5亿美元债务额度,无需额外融资即可实现上述财务目标[34] - 2024年6月30日现金及投资总额为3.89亿美元[43] - 2024年6月30日累计亏损为16.82亿美元[43] 未来发展计划 - 公司计划于2025年提交监管申请,将ORLADEYO适应症扩展至2岁以上儿童,这将是首个获批的HAE儿童口服预防治疗[14] - 公司计划于2024年底前将BCX17725(Netherton综合征治疗药物)推进临床[16]

—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the second quarter ended June 30, 2024, ...

—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2024, ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioCryst Pharmaceuticals (BCRX) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on A ...

RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast ...

文章核心观点 - BioCryst Pharmaceuticals是一家专注于开发治疗补体介导和罕见疾病的生物技术公司 [2] - 公司的主要产品是Orladeyo,占总收入的95.8% [2][10] - Orladeyo是首个获批用于预防遗传性血管性水肿(HAE)发作的口服每日疗法 [10] - Orladeyo在美国和欧洲等地区已获批上市,并正在拓展至南美等新市场 [11] - 公司预计Orladeyo在2024年将实现3.9-4亿美元的收入 [11] - 公司还有其他管线产品正在开发,包括用于补体介导疾病和罕见皮肤病的候选药物 [14] Orladeyo业务概况 - Orladeyo是公司的核心产品,占据了绝大部分收入 [2][10] - Orladeyo于2020年获FDA批准,成为首个获批用于预防HAE发作的口服每日疗法 [10] - Orladeyo在欧洲和南美等地区也陆续获批上市,拓展了国际市场 [11] - 公司正在进一步开发Orladeyo用于儿童HAE患者的适应症 [14] - 临床数据显示Orladeyo能有效控制HAE发作,且副作用较少 [15] 公司财务状况 - 公司负债较重,主要包括5.31亿美元的专利权融资和3.085亿美元的长期贷款 [17][18][19][20] - 公司短期流动性充足,但现金流量较大,短期现金流可持续性存在风险 [21][23][28] - 公司预计未来收入将快速增长,有望在2025年实现盈利 [22][23][26] - 公司估值合理,EV/销售比率略高于行业中值,但考虑到高增长,估值仍有吸引力 [26]

BioCryst Pharmaceuticals (BCRX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ...

RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. "We continue to work alongside our partner, Pint Pharma, to bring ORLADEYO to people living with HAE who are in need of n ...

RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Valencia, Spain from May 31 to June 3, 2024.  BioCryst will present two abstracts at the meeting: Adverse Health Outcomes and Patient and Physician Perspectives of Attenuat ...

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. "With this decision by COFEPRIS, ORLADEYO is now approved in four countries in the pan-Latin America region. We are p ...